Syneron Bio

Syneron Bio (元思生肽) is a biotech company developing novel macrocyclic peptide drugs, built on its proprietary Synova™ intelligent high-throughput discovery platform, with a differentiated pipeline targeting oncology and chronic diseases . Its breakout moment came in March 2025, when it signed a strategic partnership with AstraZeneca: $75 million upfront, up to $3.4 billion in development and commercialization milestones, tiered royalties, plus an equity investment from AstraZeneca, per a 5Y Capital announcement . In March 2026 the company closed a $150 million Series B led by an international biotech fund, Decheng Capital, and CDH VGC, with follow-on from an ADIA subsidiary, Temasek's True Light Capital, and Qiming Venture Partners, while existing backers — AstraZeneca, Lilly Asia Ventures, Sinovation Ventures, 5Y Capital, Hillhouse's GL Ventures, and Legend Capital — all doubled down . 暗涌Waves noted that 5Y's bet on the company was made during the market downturn, part of a cohort of portfolio companies each closing multi-billion-dollar BD deals .